Dong-A Socio Holdings to merge with Dong-A Pharm
동아쏘시오홀딩스
000640
Signal Score
Historical Avg Return (5d)
-0.11%
Data Coverage
100%n=670
Risk-adjusted indicator based on 670 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Dong-A Socio Holdings' stake in Dong-A Pharm: 100%
- • Merger Ratio (Dong-A Socio Holdings : Dong-A Pharm): 1.0000000 : 0.0000000
- • Dong-A Pharm 2025 Revenue: 726.283B KRW
- • Dong-A Pharm 2025 Operating Profit: 86.872B KRW
- • Dong-A Pharm 2025 Net Income: 107.991B KRW
AI Analysis Summary
Dong-A Socio Holdings Co.,Ltd. announced a small-scale absorption merger with its 100% wholly-owned subsidiary, Dong-A Pharm Co., Ltd. The merger ratio is 1.0000000:0.0000000, with no new shares issued. The purpose is to internalize Dong-A Pharm's consumer healthcare competitiveness and cash flow, simplify governance, enhance management efficiency, and resolve holding company discount factors. Dong-A Pharm reported 2025 revenue of 726.283B KRW, operating profit of 86.872B KRW, and net income of 107.991B KRW. The merger is expected to have no significant financial or operational impact on Dong-A Socio Holdings on a consolidated basis, as Dong-A Pharm is already a wholly-owned subsidiary. The merger is scheduled for October 1, 2026.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.